| Patent Number |
Title Of Patent |
Date Issued |
| 7449181 |
Remedies for cancer |
November 11, 2008 |
| A medicament for treating cancer for use in combination therapy with an anti-HER2 antibody, which comprises amrubicin or a pharmaceutically acceptable salt thereof as an active ingredient. |
| 7192608 |
Method of manufacturing drug granules, the drug granules and pharmaceutical preparation containi |
March 20, 2007 |
| The present invention provides coated granules using drug granules containing a water soluble drug as an active ingredient at a high density, which is superior in uniform content and stability, and which is capable of providing a pharmaceutical preparation superior in drug release co |
| 6951866 |
Bicyclic pyrimidine compounds and therapeutic use thereof |
October 4, 2005 |
| 1. A pyrimidine derivative of the formula (1) or a salt thereof; ##STR1##has an inhibitory activity of production of Th2 type cytokines such as IL-4, IL-5, etc., and is useful as an therapeutic agent for allergic diseases, autoimmune diseases such as systemic lupus erythemathosus, etc., |
| 6919361 |
Five-membered-ring compound |
July 19, 2005 |
| A 5-membered cyclic compound of the formula: ##STR1##wherein X is oxygen or sulfur, R.sup.1 is hydrogen, substituted or unsubstituted alkyl, etc., R.sup.2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, etc., Y.sup.1 is a direct bond, substituted o |
| 6902730 |
Semaphorin gene: Semaphorin W |
June 7, 2005 |
| The present invention provides Semaphorin W inhibiting neurite outgrowth, and a gene therefor, as well as other Semaphorins hybridizing to said Semaphorin W gene, modified proteins or partial peptides of said Semaphorin W, antibodies against said Semaphorin W, antisense nucleotides a |
| 6787560 |
Serotonin reuptake inhibitor |
September 7, 2004 |
| A serotonin reuptake inhibitor containing a cyclic amine represented by the following formula, a prodrug thereof, or a pharmaceutically acceptable salt of said cyclic amine or prodrug as an active ingredient: ##STR1##wherein R.sup.0 is a hydrogen atom, a halogen atom, an alkyl group, a |
| 6756048 |
Long time drug-sustained release preparation |
June 29, 2004 |
| The present invention relates to a sustained release preparation of a lipophilic drug, comprising a drug dispersion wherein the lipophilic drug and a water-soluble substance are dispersed, in a solid state at the body temperature of an animal or a human being to which the preparation is |
| 6740515 |
Recombinant adenovirus |
May 25, 2004 |
| Recombinant adenoviruses comprising the following sequences in the genome: (1) a left inverted terminal repeat: (2) a packaging signal: (3) a recombinase recognition sequence located at a region in between said left inverted terminal repeat and said packaging signal: and (4) at least one |
| 6734205 |
Substituted guanidine derivatives |
May 11, 2004 |
| A compound represented by the following formula: ##STR1##wherein R is a substituted or unsubstituted benzene ring, a fused polycyclic hydrocarbon ring which is substituted or unsubstituted, a monocyclic heterocyclic ring which is substituted or unsubstituted, a polycyclic heterocycli |
| 6713477 |
Hydroxamic acid derivatives |
March 30, 2004 |
| A hydroxamic acid derivative represented by formula (1) or a prodrug thereof, or a pharmaceutically acceptable salt thereof, which has a matrix metalo-proteinase inhibitor. |
| 6703225 |
Interferon-.alpha. |
March 9, 2004 |
| A novel human IFN-.alpha. subtype and its derivative having an unprecedentedly high specific activity, DNA encoding these proteins, an expression vector having said DNA, a transformant transformed with said expression vector, a method of producing the above human IFN-.alpha. and its |
| 6692926 |
Recombinant human SM-11044-binding receptor proteins exhibiting ligand-binding activities, and t |
February 17, 2004 |
| Transformed cells designed to express a recombinant human SMBP at an elevated level to the extent that its ligand-binding activity can be measured, and cellular membrane fractions thereof; recombinant human SMBPs isolated from the transformed cells or the cellular membrane fractions |
| 6689745 |
Agent for ameliorating pancreatic function disorder |
February 10, 2004 |
| Agents for protecting or ameliorating pancreatic cells and tissues which contains as the active ingredient a neurotrophic factor such as BDNF. By using these drugs, degenerative dropout of pancreatic cells and pancreatic hypofunction caused by diabetes, acute/chronic pancreatitis, etc. c |
| 6673772 |
Dipeptide compounds and their use as antiviral agents |
January 6, 2004 |
| A novel dipeptide compound inhibiting the enzymatic activity of HIV protease and an anti-AIDS medicine comprising this dipeptide compound as an effective component represented by formula (I) ##STR1##wherein R.sup.1, R.sup.2, and R.sup.3 independently represent C.sub.1-4 alkyl, alkoxy |
| 6664232 |
HLA-A2 restraint tumor antigen peptide originating in SART-1 |
December 16, 2003 |
| An HLA-A2 restricted tumor antigen peptide originated fromr SART-1, derivatives thereof having characteristics functionally equivalent thereto; therapeutic, prophylactic or diagnostic agents for tumors which utilize the tumor antigen peptide or its derivative, a recombinant DNA, reco |
| 6660478 |
CYP2A6 gene judgment methods |
December 9, 2003 |
| There are provided a method of determining a genotype of CYP2A6 gene on the basis of a difference in gene structures of a wild-type gene of CYP2A6 and at least one kind of mutant-type gene associated with mutation of CYP2A6 gene; the method mentioned above, wherein one kind of mutant-typ |
| 6645971 |
Quinazolinone derivatives |
November 11, 2003 |
| A compound given by general formula (1): ##STR1##[wherein T represents oxygen or sulfur atom, Y represents alkyl, cycloalkyl group, etc., ring W represents benzene ring, etc., R.sup.1 and R.sup.2 represent independently hydrogen atom, lower alkyl group, etc., and R.sup.3 represents h |
| 6599895 |
.beta.-lactam compounds and process for producing the same |
July 29, 2003 |
| Novel .beta.-lactam compound of the formula [1]: ##STR1##wherein R.sup.1 is lower alkyl or hydroxy-substituted lower alkyl, R.sup.2 is H or lower alkyl, X is O or, S, R.sup.3 is H, metal or protecting group, W is a 6- or 7-membered nitrogen-containing heterocycle optionally being sub |
| 6576441 |
Semaphorin Z and gene encoding the same |
June 10, 2003 |
| Novel semaphorin Z; a gene thereof; a partial peptide of the semaphorin Z; an antibody; a DNA or an RNA complementary to the semaphorin Z gene; a method for screening a semaphorin Z inhibitor by using the semaphorin Z; the semaphorin Z inhibitor obtained by the screening; and a CNS neuro |
| 6566094 |
Semaphorin gene: Semaphorin Y |
May 20, 2003 |
| Semaphorin Y inhibiting neurite outgrowth, and a nucleotide sequence therefor, as well as other Semaphorin sequences hybridizing to the Semaphorin Y sequence, modified proteins or partial peptides of Semaphorin Y, antibodies against Semaphorin Y, antisense nucleotides against Semapho |
| 6562599 |
Single-stranded antibody against hepatitis B virus core protein, gene thereof, and therapeutic a |
May 13, 2003 |
| A DNA characterized by coding for a single-stranded antibody capable of binding to a hepatitis B virus core protein: a single-stranded antibody coding for the DNA: a therapeutic agent for hepatitis B comprising the single-stranded antibody as the active ingredient; and a gene therapeutic |
| 6517870 |
Oral formulation comprising biguanide and an organic acid |
February 11, 2003 |
| An oral formulation comprising a biguanide and an organic acid has less unpleasant tastes such as bitterness and saltiness. |
| 6495587 |
Tricyclic indole-2-carboxylic acid compound used as NMDA receptor antagonist |
December 17, 2002 |
| The present invention provides novel tricyclic indole-2-carboxylic acids of the following chemical formula, which have potent NMDA receptor antagonistic activity. ##STR1## |
| 6472366 |
Hepatocyte growth factor for treatment of diabetes |
October 29, 2002 |
| The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), l |
| 6465254 |
Mutant loxP site and applications thereof |
October 15, 2002 |
| Highly efficient gene integration or gene replacement in the higher eucaryote including animal cells can be performed by using mutant loxP site having the following properties (a)-(c) in the present invention. (a) a nucleotide sequence wherein, in a wild-type loxP site of the followin |
| 6458798 |
Bicyclic pyrimidine compounds and therapeutic use thereof |
October 1, 2002 |
| A pyrimidine derivative of the formula (1) or a salt thereof; ##STR1##has an inhibitory activity of production of Th2 type cytokines such as IL-4, IL-5, etc., and is useful as an therapeutic agent for allergic diseases, autoimmune diseases such as systemic lupus erythemathosus, etc., |
| 6452008 |
Pyridone derivatives and process for preparing the same |
September 17, 2002 |
| A process for preparing a pyridone derivative (4), which comprises reacting the compound (1) with a hypochlorite or a hypobromite or with lead tetraacetate to give the compound (2), and reacting the compound (2) with the compound (3). Said process is preferably especially from the st |
| 6436669 |
Semaphorin genes (I) |
August 20, 2002 |
| The present invention provides a novel Semaphorin having neurite-outgrowth inhibition activity or proteins analogous thereto, peptide fragments of, or antibodies against, such proteins, genes encoding such proteins, expression vectors for said genes, transformed cells into which said |
| 6433019 |
Neurotrophic factor secretion promoters |
August 13, 2002 |
| The present invention relates to a neurotrophic factor secretagogue, in particular, to a BDNF (brain-derived neurotrophic factor) secretagogue, which comprises as an active ingredient an NO donor. The medicament of the present invention promotes the secretion of neurotrophic factors from |
| 6420381 |
Naphthyridine derivatives |
July 16, 2002 |
| A compound of the formula (I): ##STR1##wherein Ring A is substituted or unsubstituted pyridine ring, Y is substituted or unsubstituted alkyl, etc., R.sup.1 is hydrogen, or substituted or unsubstituted alkyl, etc., R.sup.2 is hydrogen or lower alkyl, R.sup.3 is lower alkyl, Z is 1) |
| 6384033 |
Amide derivative |
May 7, 2002 |
| A compound of the formula: ##STR1##whereinAr is optionally substituted phenyl, etc.; n is 0, 1 or 2;R.sup.1 is hydogen atom, optionally substituted alkyl, etc.; R.sup.2 and R.sup.3 are independently optionally substituted alkyl, etc.;R.sup.4 and R.sup.5 are independently hydrogen atom or opt |
| 6376469 |
Crystalline amrubicin hydrochloride |
April 23, 2002 |
| .beta.-Type crystalline amrubicin hydrochloride having a powder X-ray diffraction pattern having average values of diffraction angle(2.theta.) and relative intensity as given in the following table:has excellent thermal stability and is used in production of freeze-dried formulations. |
| 6329381 |
Heterocyclic compounds |
December 11, 2001 |
| The present invention relates to a heterocyclic compound of the following general formula (I): ##STR1##wherein X is sulfur atom, oxygen atom or --NR.sup.3 -- (R.sup.3 may form a heterocyclic ring or a substituted heterocyclic ring with R.sup.1 via the nitrogen atom),R.sup.1 is alkyl |
| 6300500 |
Preparation of pyridone derivatives using phthalimido containing starting material |
October 9, 2001 |
| A process for preparing a pyridone derivative (4), which comprises reacting the compound (1) with a hypochlorite or a hypobromite or with lead tetraacetate to give the compound (2), and reacting the compound (2) with the compound (3). Said process is preferably especially from the st |
| 6271251 |
Substituted guanidine derivatives, process for production thereof, and pharmaceutical uses there |
August 7, 2001 |
| A substituted guanidine derivative represented by the general formula: ##STR1##or a pharmaceutically acceptable acid addition salt thereof, is useful as a therapeutic or prophylactic agent for diseases caused by the acceleration of the sodium/proton (Na.sup.+ /H.sup.+) exchange transport |
| 6248722 |
Medicament comprising HGF gene |
June 19, 2001 |
| The present invention relates to a medicament comprising a HGF gene. The medicament of the present invention may be topically applied to the target organs so that the effects can be selectively exhibited, resulting in minimizing the side effects of HGF. |
| 6225283 |
Remedies for eating disturbance |
May 1, 2001 |
| This invention provides a therapeutic agent for the treatment of an abnormal eating behavior. The psychotic symptoms characteristic of anorexia nervosa such as apocleisis, intentional vomiting, eating in secret and the like have been treated with a tranquilizer and the like, but the |
| 6210697 |
Medicament for hypothermia treatment |
April 3, 2001 |
| A medicament containing human growth hormone (hGH), which can prevent or decrease the immunosuppression and the onset of infectious diseases such as pneumonia in a hypothermia treatment that has been recognized to show remarkable effects on the lifesaving and/or the improvement of recove |
| 6159974 |
LDL receptor gene expression promoters |
December 12, 2000 |
| LDL receptor gene expression promoters containing a 1,2,4-triazine derivative of the formula (I): ##STR1## wherein R.sup.1 is optionally substituted phenyl or heterocycle; R.sup.2 is optionally substituted phenyl, naphthyl, aralkyl, 5- or 6-membered aromatic heterocycle, alkyl, o |
| 6077829 |
Stable pharmaceutical composition of BDNF |
June 20, 2000 |
| A stable pharmaceutical composition of brain derived neurotrophic factor (BDNF) in the form of an aqueous solution or lyophilized one being suitable for a long-term storage, which contains a surfactant, especially nonionic surfactant (e.g., Tween 80) of 0.001 to 10%, whereby the poly |
| 6063564 |
Circulation thin layer liquid phase assay |
May 16, 2000 |
| An assay method capable of efficiently trapping an analyte in a certain amount of a reaction liquid in a short reaction time, the method being characterized in that only a part of a solid phase coated with a substance that specifically binds to the substance to be assayed is immersed in |
| 6048854 |
2,3-diaminopropionic acid derivative |
April 11, 2000 |
| The present invention relates to a 2,3-diaminopropionic acid derivative of the formula (1): ##STR1## or a pharmaceutically acceptable salt thereof. The compounds of the present invention are useful as a platelet aggregation inhibitor, a cancer metastasis inhibitor, a wound healin |
| 6017884 |
Method for treating acute hepatic failure |
January 25, 2000 |
| The present invention provides a novel method for treating acute hepatic failure comprising administering a therapeutically effective amount of human growth hormone (hGH) to a patient suffering from the acute hepatic failure as well as a novel therapeutic agent for acute hepatic failure |
| 5977100 |
Substituted guanidine derivatives, process for production thereof, and pharmaceutical uses there |
November 2, 1999 |
| A substituted guanidine derivative represented by the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently a hydrogen atom, an unsubstituted alkyl group, a substituted alkyl group, a halogen atom or the like; Y.sub.1, Y.sub.2, Y.sub.3, Y.sub.4, Y. |
| 5962438 |
Estrogen derivative having carriers to bone |
October 5, 1999 |
| A novel estrogen derivative represented by the formula: ##STR1## is useful for treating or preventing diseases caused by estrogen deficiency. |
| 5948786 |
Piperidinylpyrimidine derivatives |
September 7, 1999 |
| A compound of formula (1) ##STR1## wherein X.sup.1 is amino or hydroxyl, X.sup.2 is carbonyl and the like R.sup.1 is an alkyl, an aryl and the like, R.sup.2 is hydrogen and the like, and R.sup.3 is an alkyl and the like, or a pharmaceutical acceptable salt thereof is effective fo |
| 5939534 |
Factors mutated in the D1 cap region |
August 17, 1999 |
| Human ciliary neurotrophic factor (human CNTF) mutants, in which at least the amino acid residue corresponding to position 153 of wild type human CNTF has been substituted with another amino acid residue in the amino acid sequence encoding human CNTF, exhibit an activity comparable or |
| 5922356 |
Sustained release formulation |
July 13, 1999 |
| The present invention relates to a sustained release formulation used for treatment or prevention of the diseases, which contains a therapeutically effective substance as an active ingredient, collagen as a drug carrier, and glycosaminoglycan as an additive. The formulation allows contro |
| 5902806 |
Crystalline vitamin D derivative |
May 11, 1999 |
| A crystalline (5Z,7E,23S)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5,7,10(19)-trie n-1.alpha.,3.beta.,23,25-tetraol monohydrate has an excellent preservation stability, and is therefore useful as a medicine for treating or preventing bone diseases, tumor or psoriasis. |
| 5888834 |
Immunoassay plate and use thereof |
March 30, 1999 |
| An immunoassay plate for an immune complex transfer immunoassay, comprising a well type solid phase and a dip stick type solid phase which can be inserted into said well type solid phase, wherein the dip stick type solid phase is coated with either substance (A) or (B) to be mentioned be |
